AnaptysBio (NASDAQ:ANAB) Trading Down 5.9%

AnaptysBio, Inc. (NASDAQ:ANAB) shares fell 5.9% on Thursday . The company traded as low as $20.10 and last traded at $20.20. 214,966 shares were traded during trading, a decline of 31% from the average session volume of 311,290 shares. The stock had previously closed at $21.47.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ANAB. Stifel Nicolaus began coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, April 1st. Leerink Partnrs restated an “outperform” rating on shares of AnaptysBio in a research report on Tuesday. Wedbush upgraded shares of AnaptysBio from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $20.00 to $34.00 in a research report on Tuesday, March 12th. Finally, BTIG Research assumed coverage on shares of AnaptysBio in a research report on Monday, February 26th. They set a “buy” rating and a $55.00 target price for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $46.22.

AnaptysBio Trading Down 7.6 %

The firm’s 50-day moving average is $23.38 and its two-hundred day moving average is $20.55. The stock has a market cap of $530.65 million, a price-to-earnings ratio of -3.26 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.15. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. The firm had revenue of $9.01 million during the quarter, compared to the consensus estimate of $3.28 million. On average, analysts predict that AnaptysBio, Inc. will post -6.25 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at approximately $16,045,443.54. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Dennis Mulroy sold 3,065 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $23.63, for a total transaction of $72,425.95. Following the sale, the chief financial officer now directly owns 964 shares of the company’s stock, valued at approximately $22,779.32. The disclosure for this sale can be found here. Insiders sold a total of 157,005 shares of company stock worth $3,586,199 in the last 90 days. Insiders own 35.50% of the company’s stock.

Institutional Trading of AnaptysBio

Several hedge funds have recently made changes to their positions in ANAB. Woodline Partners LP grew its stake in shares of AnaptysBio by 125.1% in the 2nd quarter. Woodline Partners LP now owns 1,034,549 shares of the biotechnology company’s stock valued at $21,043,000 after buying an additional 574,987 shares during the period. First Light Asset Management LLC grew its stake in shares of AnaptysBio by 56.4% in the 4th quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock valued at $26,500,000 after buying an additional 446,372 shares during the period. Eventide Asset Management LLC purchased a new stake in shares of AnaptysBio in the 3rd quarter valued at approximately $7,669,000. Millennium Management LLC grew its stake in shares of AnaptysBio by 1,050.7% in the 4th quarter. Millennium Management LLC now owns 322,802 shares of the biotechnology company’s stock valued at $10,004,000 after buying an additional 294,750 shares during the period. Finally, Palo Alto Investors LP grew its stake in shares of AnaptysBio by 59.3% in the 4th quarter. Palo Alto Investors LP now owns 686,882 shares of the biotechnology company’s stock valued at $14,713,000 after buying an additional 255,658 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.